Inhaled gene therapy takes aim at lung nodules
NCT ID NCT07150416
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a gene therapy called Gendicine, given as a mist to breathe in, for people with multiple ground-glass lung nodules — spots that may turn into cancer. About 38 adults will receive the treatment and be monitored with CT scans to see if the nodules shrink or disappear. The goal is to find a safe, non-surgical way to control these precancerous growths.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gendicine (a gene therapy that delivers a healthy p53 gene via a modified cold virus, given as a mist to breathe in)
What this could lead to
If it works, this could offer a new way to shrink or clear precancerous lung nodules without surgery, potentially preventing lung cancer.
What could go wrong
This is a small, early-phase trial with only 38 people and no comparison group. The treatment may not shrink nodules and could cause side effects like lung irritation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••